

# Ubiquitin and Neurodegenerative Diseases

## UBIQUITİN VE NORODEJENERATİF HASTALIKLAR

Dr.İbrahim PİRİM\*

\* Department of Biochem, Medical School of Atatürk University, Erzurum, TÜRKİYE

### UBIQUITİN

In 1975, during the characterisation of calf thymus peptide hormones, Gideon Goldstein et al. Identified a protein which appeared to induce B-lympocyte differentiation (1). Interestingly, antibodies raised to this protein cross reacted with proteins of other organisms such as yeast and plants. Hence, the protein was termed ubiquitous immunopoietic peptide, later to be renamed ubiquitin (Ub). Ubiquitin was first sequenced by Schlesinger et al (2). The sequence is comprised of 76 amino acids, secondary structure includes a single alfa-helix, with four strands of B-sheet. The primary structure is highly conserved in nature and differing by only three amino acids from animal to yeast. This degree of conservation emphasises the fundamental role played by Ub in cells. Ub is extremely stable to increased temperature, changes in pH and proteolysis (3).

Cellular Ub is found in both free and conjugated forms, greater than 50% of the Ub in a particular cell may be of the free form.

Ub can form both stable and unstable conjugates with a variety of different proteins in-vivo. The stable Ub-protein conjugates include:

i. Histones; H2A and H2B, approximately 11 % of H2A and 1.5% of H2B was found to be ubiquitinated (4).

ii. Cell surface receptors; the lymphocyte homing receptor is ubiquitinated on its external domain. It is possible that the Ub may modulate the affinity of the receptor, or may be involved in signal transduction (7,8).

Unstable Ub-protein conjugates are conjugates which are normally soon degraded after formation. In this case, the ubiquitination is targeting proteins for de-


gradation, the Ub is acting as a cofactor of selective protein catabolism. It has been suggested that nearly 90% of the proteolysis of short lived proteins in mouse mammalian carcinoma cells may proceed through the Ub catalyzed pathway (9-11).

The enzymes involved in conjugation of Ub to a target protein are imaginatively termed E1, E2 and E3. E1 is Ub activating enzyme, E2s are Ub carrier proteins and E3s are proteins thought to recognize the target protein substrate (12-18). Conjugated Ub to abnormal proteins is then removed by enzymes known as Ub-C-terminal hydrolases. Ub-dependent protein degradation system with their enzymes is summarized in Fig. 1. Using DEAE column chromatography and rapid HPLC assay, three peaks of activity of Ub specific esterases were identified and separated from calf thymus (19). It has also been shown that the abundant neuron specific protein PGP 9.5 is in fact a Ub-C-terminal hydrolyze (20-22).

Ub was implicated in ATP dependent proteolysis. It was proposed that the attachment of Ub can signal degradation of the target protein. It has recently been suggested that Ub protein conjugates may be directed towards the lysosome for degradation, hence Ub may be involved in two major catabolic system. Doherty and others showed that when fibroblasts were incubated with the thiol protease inhibitor E64, which is known to inhibit lysosome cysteine cathepsins, Ub-protein conjugates accumulate in multivesicular bodies related to lysosomes (23-25). There have also been recent reports of the localization of free Ub in lysosomes of hepatoma cells (26). It now appears that Ub-protein conjugates are also enriched in lysosomes of normal cells with enrichments of up to 12 fold of the concentrations seen in all other cytoplasmic organelles. This shows that the lysosomal accumulation of Ub-protein conjugates is likely to be a normal cellular event. Ub gene organization shows some interesting features. In yeast, four different genes which code for Ub are known, termed Ubi1, Ubi2, Ubi3 and Ubi 4 (27,28). In humans, three different genes code for the Ub sequence. The genes are termed UbiA, UbiB and UbiC

Geliş Tarihi: 11.04.1994

Yazışma Adresi: Dr.İbrahim PİRİM  
Department of Biochem,  
Medical School of Atatürk University,  
Erzurum, TÜRKİYE



**Figure 1.** Proposed sequence of events in the conjugation and degradation of proteins via the ubiquitin system

1. Activation of ubiquitin by E1.
2. Transfer of the high-energy ubiquitin intermediate to E2.
3. Recycling of E1.
4. Conjugation of ubiquitin directly to the protein from E2.
5. Recycling of E2.
6. In the case of particular proteins, involvement of E3.
7. Conjugation of further molecules of ubiquitin to the protein substrate.
8. Recycling of an intact substrate and ubiquitin.
9. ATP-dependent degradation of conjugates into peptides by the 26S proteasome complex.
10. Release of amino acids from peptides.

(29,30). UbiB and UbiC genes code for polyUb sequences of three and nine copies of Ub respectively.

### WHAT IS THE RELATION BETWEEN UBIQUITIN AND NEURODEGENERATIVE DISEASES?

Much interest in the etiology and pathogenesis of Alzheimer's disease (AD) has arisen since the realiza-

tion that AO is responsible for approximately half of the cases of dementia seen. In 1987, Ub was found to be a component of the paired helical filaments (PHF) which are intermediate sized filaments (IF) found in the brains of patients with AD (31-34). PHF are the precursors of neurofibrillary tangles (NFT) (a type of inclusion body) of AD and also occur as bundles in dystrophic neurites which form plaques in the brains of AD patients. Immunochemical studies have identified the microtubule associated phosphoproteins tau as a major component of PHF. Ub is thought to be conjugated to this tau protein. Ub has also been detected in granulovascular bodies in hippocampal pyramidal neurons in AD (32-34). When other neurodegenerative diseases were studied, using polyclonal antibodies with a high affinity to conjugated Ub as a tool to detect Ub-protein conjugates, other cellular inclusions of man were found to be immunoreactive (35,36). These Ub reactive inclusions are shown in Table 1.

Example, Lewy bodies of Parkinson's disease; brainstem Lewy bodies stained intensely for both Ub and phosphorylated neurofilament proteins at the periphery. Cortical Lewy bodies stain more homogeneously for Ub. Immunohistochemistry has been used to demonstrate that diffuse Lewy body disease is more common than previously thought, accounting for approximately a third of dementia cases (37).

Example, Pick's bodies of Pick's disease; these rounded inclusion bodies stain for Ub in a punctate and weak staining pattern. Tau has also been detected in Pick's bodies. Pick's bodies are thought to be a mixture of microtubules and neurofilaments which possibly sets them aside from the family of pure IF inclusion bodies.

Example, Rosenthal fibres within astrocytic tumors; these hyaline inclusion bodies have granular irregular cores surrounded by bundles of IF. The periphery of the bodies stains strongly for Ub, the core has been found to contain the HSP B-crystallin. Glial fibrillary acidic protein (GFAP) has also been detected in the Rosenthal fibre. It is thought the fibre may be the degenerated center of a ubiquitinated GFAP IF inclusion body.

Example, Cytoplasmic bodies within muscle; these fibrillary inclusions are found in diseased states such as rare congenital myopathy. They stain strongly for Ub and are also immunoreactive for desmin.

Example, Mallory bodies of alcoholic liver disease; several structural types of these bodies are known, they contain cytokeratin with other non cytokeratin proteins. Type III Mallory bodies have a central amorphous core which does not stain for Ub, and a strong Ub staining periphery. B-crystallin has also been detected in Mallory bodies. Thus, Ub is common to many IF inclusions characteristic of major diseases, and is likely to have a fundamental but as yet unexplained

Table 1. Disease with Ubiquitin immunoreactive intracellular inclusions

Disease	Type of cell	Inclusion body	intermediate filament type
Alzheimer's disease	Neuron	Neurofibrillary tangle	(Paired helical filaments)
Parkinson's disease	Brainstem neuron	Brainstem lewy body	Neurofilament
Lewy body dementia	Cortical neuron	Cortical lewy body	Neurofilament
Pick's disease	Cortical neuron	Pick body	Neurofilament
Motor neurone disease	Spinal anterior horn neuron	Motor neurone disease inclusion	Not known
Cerebellar astrocytoma	Astrocyte	Rosenthal fibre	Glial fibrillary acidic protein
Alcoholic liver disease	Hepatocyte	Mallory body	Cytokeratin
Cytoplasmic body myopathy	Muscle	Cytoplasmic body	Desmin

role in the metabolism of the IF inclusions. It is apparent that different types of IF inclusions exist which stain differently with the anti-Ub antibody. The rarer granular cytoplasmic staining of Ub in some cells suggests that protein ubiquitination may actually occur before the inclusion body formation. The mechanism of Ub IF inclusion body formation is however unknown, but relevant information might be gained from studying metabolism of IF in virally infected cells (35-38).

Anti-Ub immunohistochemistry has been extended to study other disease states. In motor neuron disease a novel inclusion body has been identified in spinal anterior horn neurons (39). The inclusion body exists as;

- i. loose tangles or skeins of Ub positive material in the cytoplasm
- ii. tight balls of Ub positive filaments which stain strongly for Ub
- iii. multiple small rounded bodies, 2-7 um in diameter.

The inclusion bodies appear closely associated with classical Bunina bodies of motor neuron disease e.g. Ub positive material sometimes surrounds the Bunina body area. The Bunina bodies may be equivalent to the amorphous core often found in Ub filamentous inclusions (35). In motor neuron disease patients there has been shown to be a two fold increase in the expression of the poly UbiC gene in the motor cortex and spinal cord (40). This suggests the cells response is activated in this neurodegenerative disease, which may lead to the formation of the Ub filamentous inclusion.

## CONCLUSION

It has been shown that the formation of filamentous inclusion bodies is a general cellular response in many chronic neurodegenerative diseases. Ub seems to be a common factor in these inclusion bodies. There are likely to be different mechanisms for inclusion body formation, but the occurrence of Ub may be the key which leads to the elucidation of a common pathway in inclusion body formation and an explanation of the role of IF in neurodegenerative diseases. A

through study of the human enzymes involved in Ub metabolism e.g. E1, E2 is a logical starting point for further investigations into the mechanism of Ub IF inclusion body formation. A thorough understanding of this mechanism could give insights into the initial stimuli for inclusion body formation, thus directing further research into therapeutic strategies to combat the diseases.

## KAYNAKLAR

1. Goldstein G, Scheid M, Hammerli U et al. Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. *Proc Natl Acad Sci USA* 1975; 72:11-5.
2. Schlesinger dH, Goldstel G, Nial HD. Complete amino acid sequence of ubiquitin. *Biochemistry* 1975; 14(10):2214-8.
3. Cary PD. Structural studies of two high mobility group proteins from calf thymus HM14 and HM20 ubiquitin and their interaction with DNA. *Eur J Biochem* 1980; 112:577-88.
4. West MHP and Bonner WM. Histone 2B can be modified by the attachment of ubiquitin. *Nucl Acid Res* 1980; 8:4671-80.
5. Mezquita J. Effect of high mobility group nonhistone proteins HM4-20 ubiquitin and HM4-17 on histone deacetylase activity assayed in vitro. *Nucl Acid Res* 1982; 10:1781-97.
6. Lavinger L and Varshavsky A. Selective arrangement of ubiquitin and D1 protein containing nucleosomes within the *Drosophila* genome. *Cell* 1982; 28:375-85.
7. St John T, Gallatin W, Siegelman M et al. Expression cloning of a lymphocyte homing receptor cDNA ubiquitin side reactive species. *Science* 1986; 231:845-50.
8. Yarden Y, Escobedo JA, Kuang WJ et al. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors. *Nature* 1986;323:226-32.
9. Chin DT, Kuehl L, Rechsteil M et al. Conjugation of ubiquitin to denatured hemoglobin is proportional to the rate of hemoglobin degradation in hela cells. *Proc Natl Acad Sci USA* 1982; 79:5857-61.
10. Herksho A. Immunohistochemical analysis of the turnover of ubiquitin protein conjugates in cells. *J Biol Chem* 1982; 257(23):13964-70.

11. Ciechanover A and Finly D. Ubiquitin dependence of selective protein degradation demonstrated in the mammalian cell cycle mutant TS 85 Cell 1984; 37:54-66.
12. Herksho A, Heller H, Eytan E et al. Components of the ubiquitin protein ligase system. J Biol Chem 1983; 258(13):8206-14.
13. Hatfield PM. Cloning of ubiquitin activating enzyme from wheat and expression of a functional protein in E.Coli. J Biol Chem 1990; 265(26):15813-7.
14. Pickart CM and Rose IN. Functional heterogeneity of ubiquitin carrier proteins. J Biol Chem 1985; 260(3):1573-81.
15. Jentsch S and Varshavs A. The yeast DNA repair gene RAD6 encodes a ubiquitin conjugating enzyme. Nature 1987; 329:131-4.
16. Goebel MG and Yachem J. The yeast cell cycle gene DC34 encodes a ubiquitin conjugating enzyme. Science 1988; 241:1331-5.
17. Klemperer NS and Pickart CM. A novel arsenite sensitive E2 of the ubiquitin pathway purification and properties. Biochemistry 1989; 28:6035-41.
18. Elias S and Ciechanover A. J Post Trans adding of Arg moiety to acidic NH2 terminuos of proteins is required for recognition by ubiquitin protein ligase. J Biol Chem 1990; 256(26):15511-7.
19. Mayer AN, and Wilkinson KD. Detection resolution and nomenclature of multiple ubiquitin carboxyle terminal esterases from bovine calf tymus. Biochemistry 1989; 28(1):166-72.
20. Duerksen H. Affinity using pref. immobilized via Arg residues purification of ubiquitin C-terminal hydrolases. Biochemistry 1989; 28:8530-6.
21. Doran JF and Thopson RJ. Isolation of PGP9.5 a new human neuron specific protein detected by high resolution 2-dimensional electrophoresis. J Neurochem 1983, 40(6):1542-7.
22. Wilkinson KD, Lee K, Deshpande S et al. The neurone specific protein PGP9.5 is a ubiquitin C-terminal hydrolase. Science 1989; 246:671 -3.
23. Hough R and Rechsteiner M. Ubiquitin lysozyme conjugates purification and susceptibility to proteolysis. J Biol Chem 1986; 261:2391-9.
24. Hough R and Part G. Ubiquitin lyszyme conjugates identification and characterization of an ATP dependent protease from rabbit reticulocyte lysates. J Biol Chem 1986; 261(5):2400-8.
25. Doherty FJ. Ubiquitin protein conjugates accumulation in lysosome system of fibroblasts treated with cysteineproteinase inhibitors. Biochem J 1989; 263:47-55.
26. Schwartz A. Immuno electron microscopic localisation of ubiquitin in heptoma cells. EMBO J 1988; 7(10):2961-6.
27. Ozkaynak E, Finly D, Solomon M et al. The yeast ubiquitin genes. EMBO J 1987; 6(5):1429-39.
28. Redman KL and Rechsteiner M. Identification of the ubiquitin extension as ribosomal proteins S27. Nature 1989; 338:438-40.
29. Finley D and Ozkaynak E. The yeast polyubiquitin gene is essential for resistance to high temperature and other stresses. Cell 1987; 48:1034-46.
30. Lund PK. Nucleotid sequence analysis and cDNA encoding human ubiquitin. J Biol Chem 1985; 260(12)7609-13.
31. Chang HL. A role for a 70RD HSP in lysosome degradation of intracellular proteins. Science 1989; 246:382-5.
32. De Jong W. Evaluation of eye lens crystallin, the stress connection TIBS 1989; 14:365-8.
33. Robert G, Ronald J, John C et al. Hippocampal lesions in dominantly inherited Alzheimer's disease.
34. Mori H, Kondo J, Ihara Y et al. Ubiquitin is a component of PHF in Alzheimer's disease. Science 1987; 235:1641-4.
35. Lowe J, London M, Mayer RJ et al. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man including those of Parkinson disease, Pick's disease, Alzheimer's disease as well as rosenthal fibres in cerebellar astrocytomas cytoplasmic bodies in muscle and mallory bodies in alcholic liver disease. J Pathol 1988; 155:9-15.
36. Lowe J and Mayer RJ. Ubiquitin cell stress and diseases neuron system. Neuropath Appl Neurobiol 1990; 16:281-91.
37. Lennox G, Lowe J, London M et al. Diffuse lewy body disease correlative neuropathology using anti ubiquitin immunocytochemistry. J Neurol Neurosci Psych 1989; 52:1236-47.
38. Earl RT and Mangiapa EH. A putative protein sequestration site involving intermediate filaments for protein degradation by autophagy studies with transplanted sendei-viral envelope proteins in HTC cells. Biochem J 1987; 241:809-15.
39. Lowe J, Lennox G, London M et al. Filamentous inclusion body within anterior horn neurones in motor neurone disease defined by immunocytochemical localization of ubiquitin. Neurosci Letters 1988; 94:203-10.
40. Heggie P and London M. Ubiquitin gene expression in brain and spinal cord in motor neurone disease. Neurosci Letters 1989;102:343-8.